Emerging PSMA Radioligand Therapy Shows Benefits for Metastatic Castration-Resistant Prostate Cancer
The PSMA-targeted modality 177Lu-PNT2002 improved radiographic progression-free survival by 29 percent in patients with mCRPC in comparison to ARPI therapy, according to new phase 3 trial data presented at the ESMO Congress in Spain.
Emerging research presented at the European Society of Medical Oncology (ESMO) Congress suggests that the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy 177Lu-PNT2002 offers significant advantages over androgen-receptor pathway inhibitor (ARPI) treatment of PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC).
In the SPLASH phase 3 randomized trial, researchers compared the administration of 177Lu-PNT2002 (6.8 GBq every eight weeks for up to four treatment cycles) to ARPI therapies (abiraterone and enzalutamide) in 412 patients with mCRPC.1
The researchers found that 177Lu-PNT2002 (Lantheus) bolstered radiographic progression-free survival (rPFS) by 29 percent and led to a 3.5 month increase in median rPFS (9.5 months vs. 6.5 months) in contrast to ARPI therapy.1,2
The use of the radioligand therapy 177Lu-PNT2002 was also associated with a longer median duration of response (9.4 months vs. 7.3 months), more than double the PSA50 response rate (35.7 percent vs. 14.6 percent) and longer median biochemical progression-free survival (seven months vs. 3.9 months) in comparison to ARPI modalities, according to the study authors.2
In recent phase 3 trial research presented at the ESMO Congress 2024, researchers found that the PSMA-targeted radioligand 177Lu-PNT2002 offered significantly improved median radiographic progression-free survival (rPFS), biochemical progression-free survival (bPFS) and treatment duration response in comparison to androgen-receptor pathway inhibitor (ARPI) treatment of PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC).
“These initial data underscore the importance of PSMA-targeted RLTs, including 177Lu-PNT2002, as potential treatment options for patients who have limited choices after progressing on ARPI therapy,”noted Oliver Sartor, M.D., the director of radiopharmaceutical trials and a professor of medical oncology at the Mayo Clinic in Rochester, Minnesota.
(Editor's note: For related content on imaging for prostate cancer, click here.)
The researchers also pointed out that 177Lu-PNT2002 had lower safety risks than ARPI therapy. Specifically, patients in the 177Lu-PNT2002 cohort had a lower rate of treatment-related serious adverse events (AEs) (2.2 percent vs. 3.8 percent). The study authors said those who had 177Lu-PNT2002 had a greater than threefold lower rate of halted or reduced treatment due to treatment-emergent adverse events (TEAEs) in comparison to patients who had ARPI therapy (3 percent vs. 11.5 percent).1,2
References
1. Lantheus. Lantheus presents results from the primary analysis of phase 3 pivotal SPLASH trial in PSMA-positive metastatic castration-resistant prostate cancer during ESMO Congress 2024. Available at: https://investor.lantheus.com/news-releases/news-release-details/lantheus-presents-results-primary-analysis-phase-3-pivotal . Published September 15, 2024. Accessed September 16, 2024.
2. Sartor O, Jiang DM, Smoragiewicz M, et al. Efficacy of 177LU-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Presented at the European Society for Medical Oncology (ESMO) Congress September 13-17, 2024, Barcelona, Spain. Available at: https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session/list? . Accessed September 16, 2024.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
